Company / Cash & Equivalents
Avanos Medical, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$89.8M
FY2025
5-year range
$87.7M / $127.7M
FY2021-FY2025
Trend
-16.6%
vs FY2024
Sector context
#118 of 152
Health Care
What the data says
Avanos Medical, Inc.'s cash & equivalents of $90M is lower than 78% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $88M in FY2023 to $385M in FY2018.
Based on SEC 10-K filings.
$90M in FY2025 with a 5-year CAGR of -4.2%.
Improved from $88M to $90M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -11.1%
- 5-Year CAGR
- -4.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 152This company $89.8M Sector average $1.2B
▼
-92.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -4.2%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 16.6% year-over-year.
- Ranks #118 out of 152 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score 1.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $89.8M | -16.6% |
| FY2024 | $107.7M | +22.8% |
| FY2023 | $87.7M | -31.3% |
| FY2022 | $127.7M | +7.8% |
| FY2021 | $118.5M | +6.3% |
| FY2020 | $111.5M | -45.7% |
| FY2019 | $205.3M | -46.6% |
| FY2018 | $384.5M | +75.0% |
| FY2017 | $219.7M | +93.2% |
| FY2016 | $113.7M | -12.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026